ADC Therapeutics SA Adjustments For Increase Decrease In Other Liabilities
ADC Therapeutics SA (ADCT) reported Adjustments For Increase Decrease In Other Liabilities of -$16.21 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities · last filed 2023-11-07
- ADC Therapeutics SA adjustments for increase decrease in other liabilities for the quarter ending 2023-09-30 was $90.00K, a 98.36% decline year-over-year.
- ADC Therapeutics SA adjustments for increase decrease in other liabilities for the quarter ending 2023-06-30 was -$4.21M, a 142.60% decline year-over-year.
- ADC Therapeutics SA adjustments for increase decrease in other liabilities for the quarter ending 2023-03-31 was -$12.09M.
- ADC Therapeutics SA adjustments for increase decrease in other liabilities for the quarter ending 2022-12-31 was $15.42M, a 92.16% increase year-over-year.
| Period end | Adjustments For Increase Decrease In Other Liabilities 3 month | Adjustments For Increase Decrease In Other Liabilities 6 month | Adjustments For Increase Decrease In Other Liabilities 9 month | Adjustments For Increase Decrease In Other Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $90.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$4.12M derived: sum of 2 quarters · filed 2023-11-07 | -$16.21M 6-K · filed 2023-11-07 | -$790.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$4.21M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$16.30M 6-K · filed 2023-08-08 | -$880.00K derived: sum of 3 quarters · filed 2023-08-08 | $4.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$12.09M 6-K · filed 2023-05-09 | $3.33M derived: sum of 2 quarters · filed 2023-05-09 | $8.80M derived: sum of 3 quarters · filed 2023-11-07 | $18.67M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $15.42M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $20.89M derived: sum of 2 quarters · filed 2023-11-07 | $30.76M derived: sum of 3 quarters · filed 2023-11-07 | $20.10M 20-F · filed 2023-03-15 |
| 2022-09-30 | $5.47M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $15.35M derived: sum of 2 quarters · filed 2023-11-07 | $4.68M 6-K · filed 2023-11-07 | $12.70M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $9.88M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$791.00K 6-K · filed 2023-08-08 | $7.23M derived: sum of 3 quarters · filed 2023-08-08 | $12.88M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$10.67M 6-K · filed 2023-05-09 | -$2.64M derived: sum of 2 quarters · filed 2023-05-09 | $3.01M derived: sum of 3 quarters · filed 2023-05-09 | $7.18M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $8.02M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $13.67M derived: sum of 2 quarters · filed 2023-03-15 | $17.85M derived: sum of 3 quarters · filed 2023-03-15 | $12.52M 20-F · filed 2023-03-15 |
| 2021-09-30 | $5.65M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $9.83M derived: sum of 2 quarters · filed 2022-11-08 | $4.50M 6-K · filed 2022-11-08 | $14.12M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $4.18M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | -$1.16M 6-K · filed 2022-08-09 | $8.47M derived: sum of 3 quarters · filed 2023-03-15 | $9.01M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$5.33M 6-K · filed 2022-05-09 | $4.29M derived: sum of 2 quarters · filed 2023-03-15 | $4.83M derived: sum of 3 quarters · filed 2023-03-15 | $9.37M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $9.62M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $10.16M derived: sum of 2 quarters · filed 2023-03-15 | $14.70M derived: sum of 3 quarters · filed 2023-03-15 | $14.95M 20-F · filed 2023-03-15 |
| 2020-09-30 | $541.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $5.08M derived: sum of 2 quarters · filed 2021-11-02 | $5.32M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $4.54M derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $4.78M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $242.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $1.72M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $3.26M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |